European CRO Selects OmniComm eClinical Solutions for Phase III Study
Ft. Lauderdale, FL-based OmniComm Systems, Inc. (OTC: OMCM.OB), announced that it has been selected by a leading European-based CRO to provide eClinical solutions for a pivotal Phase III study in rheumatoid arthritis (RA). This RA study is expected to last 48 months and enroll close to 300 patients in 20 sites located in Europe.
“We are very excited to be working again with this leading CRO on this pivotal study,” commented Stephen Johnson, OmniComm’s COO. “We appreciate their ongoing trust in us and will continue to deliver superior products and services to them. We are also very excited about our continued expansion into the European marketplace. We have recently opened up another office in the United Kingdom, OmniComm Ltd., which will allow us to broaden our service and support offering even further.” OmniComm Systems also has international offices in Bonn, Germany and Tula, Russia.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
